ANRO
Price
$24.78
Change
-$0.16 (-0.64%)
Updated
Jul 2 closing price
Capitalization
869.63M
45 days until earnings call
Intraday BUY SELL Signals
PRAX
Price
$319.07
Change
-$8.72 (-2.66%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
8.88B
36 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANRO vs PRAX

ANRO vs PRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANRO vs. PRAX commentary
Jul 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a StrongBuy and PRAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2026
Stock price -- (ANRO: $24.78 vs. PRAX: $318.52)
Brand notoriety: ANRO and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 100% vs. PRAX: 36%
Market capitalization -- ANRO: $869.63M vs. PRAX: $8.88B
ANRO [@Biotechnology] is valued at $869.63M. PRAX’s [@Biotechnology] market capitalization is $8.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, ANRO is a better buy in the long-term than PRAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 5 TA indicator(s) are bullish while PRAX’s TA Score has 6 bullish TA indicator(s).

  • ANRO’s TA Score: 5 bullish, 5 bearish.
  • PRAX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than ANRO.

Price Growth

ANRO (@Biotechnology) experienced а -2.06% price change this week, while PRAX (@Biotechnology) price change was -2.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

ANRO is expected to report earnings on Aug 19, 2026.

PRAX is expected to report earnings on Aug 10, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($8.88B) has a higher market cap than ANRO($870M). ANRO YTD gains are higher at: 39.213 vs. PRAX (11.213). ANRO has higher annual earnings (EBITDA): -71.22M vs. PRAX (-357.2M). PRAX has more cash in the bank: 787M vs. ANRO (264M). PRAX has less debt than ANRO: PRAX (1.44M) vs ANRO (23.2M). ANRO (0) and PRAX (0) have equivalent revenues.
ANROPRAXANRO / PRAX
Capitalization870M8.88B10%
EBITDA-71.22M-357.2M20%
Gain YTD39.21311.213350%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M787M34%
Total Debt23.2M1.44M1,617%
TECHNICAL ANALYSIS
Technical Analysis
ANROPRAX
RSI
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
89%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 20 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
Bearish Trend 4 days ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ANRO
Daily Signal:
Gain/Loss:
PRAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COMP12.620.07
+0.56%
Compass
PACHU10.31N/A
N/A
Pioneer Acquisition I Corp
QFIN15.81N/A
N/A
Qfin Holdings Inc
XFOR4.02N/A
N/A
X4 Pharmaceuticals Inc
NXB2.14-0.02
-0.93%
Nextboat Inc.

ANRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with NUVL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
-0.64%
NUVL - ANRO
38%
Loosely correlated
+0.11%
OMER - ANRO
38%
Loosely correlated
-1.38%
PRAX - ANRO
38%
Loosely correlated
-0.34%
IMTX - ANRO
37%
Loosely correlated
+1.02%
RXRX - ANRO
34%
Loosely correlated
+3.54%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
N/A
BEAM - PRAX
40%
Loosely correlated
N/A
ANRO - PRAX
38%
Loosely correlated
-0.64%
BHVN - PRAX
37%
Loosely correlated
+1.27%
RAPP - PRAX
35%
Loosely correlated
N/A
VERU - PRAX
35%
Loosely correlated
N/A
More